C2i Genomics News
13 articles
Cancer care startup C2i Genomics acquired by Veracyte for up to $95 million | CTech
Israeli startup C2i Genomics, a company that has developed a test platform using whole-genome tumor sequencing, is being acquired by cancer diagnostics company Veracyte for up to $95 million. The deal includes $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years. Veracyte plans to use C2i Genomics technology to develop a muscle-invasive bladder cancer MRD test and further MRD tests in several of its focused indications.
Acquisition
AstraZeneca to Evaluate C2i Genomics' Cancer Detection, Monitoring Platform
AstraZeneca will evaluate C2i Genomics whole-genome minimal residual disease assay and cancer-monitoring platform for use in clinical research and drug development efforts. The collaboration aims to improve treatment monitoring and clinical trial recruitment. C2i Genomics platform applies artificial intelligence to whole-genome sequencing data to detect minimal residual disease and treatment resistance. AstraZeneca will validate the assay and platform on patient-derived samples. The collaboration is an extension of a previous partnership between the two companies. C2i Genomics previously participated in AstraZenecas BeyondBio Innovation Hub program.
PartnersCustomers
C2i Genomics, Karkinos Healthcare Partner to Bring AI-Powered Cancer R&D to India
C2i Genomics has announced a strategic partnership with Karkinos Healthcare to develop the first whole-genome sequencing (WGS) MRD test in India. The partnership aims to improve diagnostic labs in India by providing them with the ability to validate and monitor the quality of whole-genome cancer screening and minimal residual disease (MRD) products faster. This partnership will expand MRD monitoring within the Karkinos health system and its partners using C2i Genomics ultrasensitive whole-genome analysis. C2i Genomics SaaS solution utilizes machine learning and AI technology to analyze patients blood for early detection of cancer recurrence or resistance. The partnership is expected to drive more informed treatment decisions and personalized treatment plans.
PartnersExpand
C2i Genomics Partners with Twist Bioscience to Launch Reference Materials for Whole-Genome Cancer Detection
A blood test that can identify recurrent cancer
C2i Genomics, a startup founded by Dr. Asaf Zviran, has developed a personalized medicine approach for the early detection of persistent or recurrent cancer cells. The company has raised over $100 million in financing and has signed a collaboration agreement with Premier, an American healthcare improvement company. C2is platform aims to solve the problem of over- or undertreatment of solid tumors by providing real-time measurements of cancer levels in patients blood. The platform scans the entire genome to find unique mutations in each patient and can be processed at any genomic sequencing lab. C2i Genomics was a finalist for the 2021 Spinoff Prize awarded by Nature and Merck.
InvestmentPartners
C2i Genomics and Premier Inc. Team Up to Bring AI-Powered Personalized Cancer Detection and Treatment Monitoring to U.S. Healthcare Providers
C2i Genomics has signed a collaboration agreement with Premier Inc. to bring AI-powered cancer detection and monitoring to health systems in the Premier network. The partnership will establish a real-world evidence council and develop a white paper on best practices in point-of-care solutions. C2i Genomics will also partner with eight Premier members to implement their C2-Intelligence Platform, a cancer diagnostics service. The platform uses whole-genome sequencing and AI to provide sensitive cancer detection. The partnership will leverage both companies data sets to uncover new oncology insights. C2i Genomics recently partnered with NovogeneAIT Genomics and raised over $100M in financing.
Partners
C2i Genomics, NovogeneAIT Genomics Partner to Launch Cancer Detection Platform in Southeast Asia
C2i Genomics has signed an agreement with NovogeneAIT Genomics to launch its C2-Intelligence Platform for minimal residual disease detection in Southeast Asia. The platform uses artificial intelligence and whole-genome analysis to detect minimal residual disease in blood samples from cancer patients. NovogeneAIT will act as a reference lab for the platform and has been given a nonexclusive license to distribute and market C2is pharmaceutical and diagnostic services in the region. Financial terms were not disclosed. Earlier this year, C2i raised $100 million in private financing.
PartnersInvestment
C2i, a genomics SaaS product to detect traces of cancer, raises $100M Series B
C2i Genomics, a company that has developed software for detecting residual cancer, has raised $100 million in a Series B funding round led by Casdin Capital. The software developed by C2i Genomics is 100 times more sensitive in detecting residual disease compared to traditional methods. It allows doctors to order a liquid biopsy, sequence the entire genome, and upload it to the C2i platform. The software then identifies faint patterns that indicate the presence of cancer and can inform if its growing or shrinking. While the product is not FDA-approved yet, it is being used in clinical research and drug development at various institutions. The funding will be used to accelerate clinical development and commercialization of C2i Genomics C2-Intelligence Platform.
Investment
C2i Genomics Acquires Sequencing Lab QNA Dx
C2i Genomics has acquired CLIA-certified sequencing lab QNA Dx to accelerate the commercialization of its MRDetect cancer monitoring platform. The financial terms of the transaction were not disclosed. The acquisition will help C2i scale its cancer sample processing capacity and offer centralized lab services, potentially leading to reimbursement for MRDetect as a laboratory-developed test. C2i aims to transform patient care and take the technology to the clinic. Last year, the company closed a $12 million Series A financing round.
AcquisitionPartners
C2i Genomics Announces Strategic New Hires to Expand Commercialization of Whole Genome Cancer Detection Platform - Benzinga
C2i Genomics has announced strategic new hires and board appointments to revolutionize disease monitoring in clinical oncology and therapeutics development. The company has joined BloodPAC, a consortium dedicated to accelerating the development and validation of liquid biopsy assays in oncology. C2i Genomics cancer intelligence technology utilizes whole-genome sequencing and artificial intelligence to detect patient-specific cancer patterns in small blood samples. The technology aims to improve cancer patient outcomes and accelerate drug development. The company has hired Mark Oldroyd as Chief Business Officer, Ravi Kandasamy as Vice President for Research & Development, and Alex Parker as a board member. The new hires bring decades of experience from leading pharmaceutical, genomics, and diagnostics companies. C2i Genomics is focused on expanding partnerships and aims to bring its breakthrough technology to the clinic and drug development space faster.
PartnersExpand
Cancer recurrence monitoring co C2i Genomics raises $12m
C2i Genomics, an Israeli cancer recurrence monitoring company, has raised $12 million in its Series A financing. The funding will be used to develop and validate C2i Genomics personalized, real-time solution for monitoring recurrence and treatment response for various types of solid cancers. The company has developed a breakthrough tumor pattern recognition approach for liquid biopsy. C2i Genomics technology has been validated through clinical cohorts and was recently published in Nature Medicine.
Investment
Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring - Nature Medicine
The article discusses the advancements in cancer detection using liquid biopsies and circulating tumor DNA (ctDNA). The research, supported by various grants and awards, focuses on the development of MRDetect, a method for sensitive tumor detection and classification using plasma cell-free DNA methylomes. The study highlights the accuracy of tumor fraction estimation and the effectiveness of sequencing error suppression techniques. The work involves contributions from multiple institutions, including the New York Genome Center and Weill Cornell Medicine. The research is expected to have a positive impact on C2i Genomics, a company co-founded by some of the authors, by advancing their capabilities in non-invasive cancer diagnostics.
Genomic Testing Cooperative (GTC) and C2i Genomics Announce Collaboration to Offer Liquid Biopsy Testing for Staging and Monitoring Solid Tumors Based on Pattern Recognition of Whole Genome DNA Signature
Genomic Testing Cooperative (GTC) and C2i Genomics have announced a collaboration to develop liquid biopsy tests for the staging and monitoring of solid tumors. GTC will adapt C2i Genomics AI-based pattern recognition technology for distribution to its members. The collaboration will initially focus on lung, colon, breast, and melanoma cancers. The partnership aims to provide highly accurate personalized monitoring for cancer patients. GTC will perform sequencing and participate in technical and clinical validation, while C2i will be responsible for AI-based analysis and recruitment of samples. GTC operates as a cooperative molecular testing company, while C2i provides cloud-based cancer diagnostic services.
Partners
